The overall goals of this AIDS-CSG are to establish a clinical center for the treatment of HIV infection and related disorders in the OSU Hospitals referral area and to establish a related multidisciplinary basic research effort. Specific objectives include: 1. Establish a cohort of HIV infected patients. 2. Establish a local core of clinical and basic scientists committed to studying this infection. 3. Enter as many of our cohorts as possible into our General Clinical Research Center database - CLINFO. 4. Conduct therapeutic interventions during various stages of HIV infection and follow the course of infection after intervention. 5. Provide adequate resources for the diagnosis and treatment of HIV related conditions such as opportunistic infections and malignancies. 6. Conduct basic science projects to study the epidemiology, pathogenesis, immunology and natural history of HIV infection. 7. Have the cohort available for future studies. Project 1 establishes a cohort of patients, tracks the course of HIV infection, provides the clinical database for other projects, and tests the efficacy and safety of investigational treatments for opportunistic infections. Project 2 tests the potential of alpha-, beta- and gamma-interferons, in combination with AZT, as therapeutic agents. Project 3 tests the hypothesis that vasoactive intestinal peptide (VIP) or other peptides may be responsible for HIV associated diarrhea. Project 5 will assess the effects of HIV infections on Ia expression by human monocytes, the effects of AZT treatment on Ia expression and the ability of monocytes from infected individuals to control growth of MAC. Support services will be supplied by an administrative core, a laboratory core, and a database and analysis core.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI025924-04
Application #
3546973
Study Section
Special Emphasis Panel (SRC (05))
Project Start
1987-09-30
Project End
1992-08-31
Budget Start
1990-09-01
Budget End
1991-08-31
Support Year
4
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
Schools of Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Brashers, Dale E; Basinger, Erin D; Rintamaki, Lance S et al. (2017) Taking Control: The Efficacy and Durability of a Peer-Led Uncertainty Management Intervention for People Recently Diagnosed With HIV. Health Commun 32:11-21
Peterson, Jennifer L; Rintamaki, Lance S; Brashers, Dale E et al. (2012) The forms and functions of peer social support for people living with HIV. J Assoc Nurses AIDS Care 23:294-305
Winham, Stacey J; Slater, Andrew J; Motsinger-Reif, Alison A (2010) A comparison of internal validation techniques for multifactor dimensionality reduction. BMC Bioinformatics 11:394
Raboud, Janet M; Diong, Christina; Carr, Andrew et al. (2010) A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin Trials 11:39-50
Skowron, Gail; Spritzler, John G; Weidler, Jodi et al. (2009) Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr 50:250-8
Sax, Paul E; Tierney, Camlin; Collier, Ann C et al. (2009) Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 361:2230-40
Williams, Pl; Wu, Jw; Cohn, Se et al. (2009) Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution. HIV Med 10:290-301
Ma, Qing; Forrest, Alan; Rosenkranz, Susan L et al. (2008) Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. Biopharm Drug Dispos 29:91-101
Collier, Ann C; Tierney, Camlin; Downey, Gerald F et al. (2008) Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV. HIV Clin Trials 9:91-102
Demeter, Lisa M; DeGruttola, Victor; Lustgarten, Stephanie et al. (2008) Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin Trials 9:11-25

Showing the most recent 10 out of 97 publications